
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc is poised for significant financial growth, with projected total revenues reaching $373 million by 2032, up from earlier estimates of $339 million, driven by the company's strategic expansion into the Medicaid Drug Rebate Program. The organization is consistently adding treatment centers and anticipates that positive outcomes from the CHOPIN trial and the National Drug Rebate Agreement will enhance drug adoption and improve profit margins. Additionally, Delcath has revised its revenue guidance for 2025, expecting product revenues of $95 million, a notable increase from previous forecasts, indicating strong growth potential even amidst anticipated pricing pressures.
Bears say
Delcath Systems Inc. has faced significant challenges, with preliminary third-quarter 2025 revenues reported at $20.5 million, representing a 15% quarter-over-quarter decline from $24.2 million and falling short of consensus estimates of $23.8 million. Management has notably lowered its full-year revenue guidance for FY2025 to a range of $83-$85 million from the previous $93-$96 million, which indicates a substantial downward revision in expectations. Additionally, the impact of discounts from HEPZATO's participation in the NDRA program and unexpected summer seasonality affecting patient scheduling suggests ongoing operational uncertainties that contribute to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares